A new paradigm for drug discovery

For a neo-biotech like Cyclica, the participation of technology is inseparable from the process of drug discovery.


A computational approach to poly-pharmacology

Our platforms, Ligand Express® and Ligand Design™, use a proteome-wide lens to evaluate multiple novel and rare on- and off-target interactions simultaneously.

Cyclica's platform takes a computational approach to polypharmacology
Cyclica's platform is powered by innovative machine learning engines MatchMaker and POEM


Our platforms are powered by innovative machine learning engines

Our deep learning-enabled MatchMaker™ and machine learning-enabled POEM™ technologies use machine learning to marry knowledge- and structure-based approaches to generate high quality predictions.

Our core scientific values

We’ve walked in your shoes for decades, and we’d love to help advance your impact.

A polypharmacological view

Our unique, multi-target approach allows us to evaluate novel and rare on- and off-target interactions simultaneously.

Custom proteomes on-demand

We utilize human and custom proteomes to accommodate animal and plant-based research, viral targets, and more.

Biophysics matters

Screening for actives alone has limited upside. We integrate science with a structure-based view, working not just on targets but with everything downstream, too.

We don’t overpromise

We never compromise on data quality or integrity, so you can trust our results. We set a high bar and live by it every day.

Data-driven decisions

We increase the probability of success by applying data-driven approaches to arrive at answers quickly, without compromising quality or integrity.

Our purpose is patients

We’re in this for one reason and one reason alone: to get medicines to patients faster and more precisely.

A proteome-wide lens

Our commitment to collaborating holistically improves the odds of reaching milestones dramatically. Embrace the complexity of disease with Cyclica.